The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | H | Systemic hormonal preparations, excl. Sex hormones and insulins | |
2 | H05 | Calcium homeostasis | |
3 | H05B | Anti-parathyroid agents | |
4 | H05BX | Other anti-parathyroid agents | |
5 | H05BX02 | Paricalcitol |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
Route | Amount |
---|---|
ORAL - Oral | 2 ug |
PAREN - Parenteral | 2 ug |
Active Ingredient | Description | |
---|---|---|
Paricalcitol |
Paricalcitol is a synthetic, biologically active vitamin D analog of calcitriol with modifications to the side chain (D2) and the A (19-nor) ring. Unlike calcitriol, it is a selective vitamin D receptor (VDR) activator. Paricalcitol reduces parathyroid hormone (PTH) levels by inhibiting parathyroid proliferation and decreasing PTH synthesis and secretion, with minimal impact on calcium and phosphorus levels, and can act directly on bone cells to maintain bone volume and improve mineralization surfaces. |
Title | Information Source | Document Type | |
---|---|---|---|
ZEMPLAR Capsule, soft | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
ZEMPLAR Solution for injection | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.